David Cibula
Overview
Explore the profile of David Cibula including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
256
Citations
5451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mayer A, Cibula D
Eur J Surg Oncol
. 2024 Oct;
50(12):108739.
PMID: 39418833
Prehabilitation aims to improve patients' physical condition before a stressful event, such as surgery, and enhance recovery. Despite its potential benefits, many emerging prehabilitation programs face challenges in enrolling or...
12.
Slomovitz B, Cibula D, Lv W, Ortac F, Hietanen S, Backes F, et al.
J Clin Oncol
. 2024 Oct;
43(3):251-259.
PMID: 39411812
Mismatch repair-deficient (dMMR) endometrial cancer (EC) is an inflamed phenotype with poor outcomes when meeting high-risk criteria and limited treatment options in the adjuvant setting. We report protocol-prespecified subgroup analysis...
13.
Pinto P, Moro F, Alcazar J, Alessi S, Avesani G, Benesova K, et al.
Gynecol Oncol
. 2024 Oct;
191:132-142.
PMID: 39393218
Background: The aim was to evaluate the performance of the Peritoneal Cancer Index (PCI) using imaging (ultrasound, contrast-enhanced computed tomography (CT), and whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) in assessing...
14.
Ng Z, Manchanda R, Lopez A, Obermair A, Dostalek L, Pareja R, et al.
Gynecol Oncol
. 2024 Oct;
191:95-99.
PMID: 39378742
Objective: Patients with TNM T1a cervical cancer have excellent prognosis; however, the risk for recurrence remains an issue of concern and management guidelines are based on limited data. Here we...
15.
Bizzarri N, Querleu D, Ramirez P, Dostalek L, van Lonkhuijzen L, Giannarelli D, et al.
Eur J Cancer
. 2024 Sep;
211:114310.
PMID: 39270379
Aim: The aim of this study was to assess whether the use of sentinel lymph node (SLN) in addition to lymphadenectomy was associated with survival benefit in patients with early-stage...
16.
Bizzarri N, Abu-Rustum N, Plante M, Ramirez P, Chiva L, Falconer H, et al.
Int J Gynecol Cancer
. 2024 Aug;
34(11):1805-1808.
PMID: 39209433
After the publication of the Laparoscopic Approach to Cervical Cancer (LACC) trial, open surgery has become the standard approach for radical hysterectomy in early stage cervical cancer. Recent studies assessed...
17.
Fricova L, Kommoss S, Scambia G, Ferron G, Kocian R, Harter P, et al.
Gynecol Oncol
. 2024 Aug;
190:179-185.
PMID: 39197417
Introduction: Fertility-sparing treatment (FST) for patients with cervical cancer intends to achieve oncologic outcomes comparable to those after radical treatment while maximizing reproductive outcomes, including the ability to conceive and...
18.
Angeles M, Agusti N, Bonaldo G, Bizzarri N, Bilir E, Piedimonte S, et al.
Int J Gynecol Cancer
. 2024 Aug;
34(10):1522-1528.
PMID: 39181697
In March 2024, 12 European Network of Young Gynae Oncologists- (ENYGO-IJGC) Editorial Fellows conducted 10 interviews with senior opinion leaders on original and controversial topics in the field of gynecologic...
19.
Lanickova T, Hensler M, Kasikova L, Vosahlikova S, Angelidou A, Pasulka J, et al.
Clin Cancer Res
. 2024 Aug;
31(1):164-180.
PMID: 39163092
Purpose: Patients with high-grade serous ovarian carcinoma (HGSOC) are virtually insensitive to immune checkpoint inhibitors (ICI) employed as standalone therapeutics, at least in part reflecting microenvironmental immunosuppression. Thus, conventional chemotherapeutics...
20.
OMalley D, Myers T, Wimberger P, Van Gorp T, Redondo A, Cibula D, et al.
Future Oncol
. 2024 Jul;
20(32):2423-2436.
PMID: 39082675
At first recurrence, platinum-sensitive ovarian cancer (PSOC) is frequently treated with platinum-based chemotherapy doublets plus bevacizumab, then single-agent bevacizumab. Most patients' disease progresses within a year after chemotherapy, emphasizing the...